Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases

Papers of special note have been highlighted as: •• of considerable interest

References

• 1. The Top 10 Causes of Death. WHO, Geneva, Switzerland (2020).
  Google Scholar
• 2. Diamond M, Feliciano HLP, Sanghavi D et al. Acute respiratory distress syndrome. StatPearls Publishing, Treasure Island (FL) (2022).
  Google Scholar
• 3. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. British J. Clin. Pharmacol. 56(6), 588–599 (2003).
  Medline CASGoogle Scholar
• 4. Patra JK, Das G, Fraceto LF et al. Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnol. 16(1), 1–33 (2018).
  MedlineGoogle Scholar
• 5. Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu. Rev. Pathol. Mech. Dis. 6, 147–163 (2011).
  CASGoogle Scholar
• 6. Childhood Diseases. UNICEF, USA (2020).
  Google Scholar
• 7. Fletcher AE, Breeze E, Shetty PS. Antioxidant vitamins and mortality in older persons: findings from the nutrition add-on study to the Medical Research Council Trial of assessment and management of older people in the community. Am. J. Clin. Nutr. 78(5), 999–1010 (2003).
  Medline CASGoogle Scholar
• 8. Lai CC, Shih TP, Ko WC et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int. J. Antimicrobial Agents 55(3), 105924 (2020).
  Medline CASGoogle Scholar
• 9. Shaver CM, Bastarache JA. Clinical and biological heterogeneity in ARDS: direct versus indirect lung injury. Clin. Chest Med. 35(4), 639–653 (2014).
  MedlineGoogle Scholar
• 10. Bulla A, Hitze KL. Acute respiratory infections: a review. Bull. World Health Organ. 56(3), 481 (1978).
  Medline CASGoogle Scholar
• 11. Thomas M, Bomar PA. Upper respiratory tract infection. StatPearls Publishing, Treasure Island (FL) (2022).
  Google Scholar
• 12. Mahashur A. Management of lower respiratory tract infection in outpatient settings: focus on clarithromycin. Lung India 35(2), 143 (2018).
  MedlineGoogle Scholar
• 13. Dasaraju PV, Liu C. Chapter 93: Infections of the Respiratory System. University of Texas Medical Branch at Galveston, Galveston, 1 (1996).
  Google Scholar
• 14. Lapner ST, Kearon C. Diagnosis and management of pulmonary embolism. BMJ 346, (2013).
  MedlineGoogle Scholar
• 15. Coon WW. Risk factors in pulmonary embolism. Surg. Gynecol. Obstet. 143(3), 385–390 (1976).
  Medline CASGoogle Scholar
• 16. Kucher N, Rossi E, De Rosa M et al. Massive pulmonary embolism. Circulation 113(4), 577–582 (2006).
  MedlineGoogle Scholar
• 17. Herrero R, Sanchez G, Lorente JA. New insights into the mechanisms of pulmonary edema in acute lung injury. Ann. Transl. Med. 6(2), 32 (2018).
  MedlineGoogle Scholar
• 18. Fein AM, Calalang-Colucci MG. Acute lung injury and acute respiratory distress syndrome in sepsis and septic shock. Crit. Care Clin. 16(2), 289–317 (2000).
  Medline CASGoogle Scholar
• 19. Xie M, Liu X, Cao X et al. Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017. Respir. Res. 21(1), 1–13 (2020).
  MedlineGoogle Scholar
• 20. Anderson CF, Grimmett ME, Domalewski CJ et al. Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 12(1), e1586 (2020). •• Describes current developments in the design of inhaled nanomaterial-based drug-delivery systems and examines a number of representative systems to highlight the fundamental design concepts that can lead to increased treatment efficacy for common respiratory disorders.
  Medline CASGoogle Scholar
• 21. World Health Statistics. WHO, Geneva, Switzerland (2022).
  Google Scholar
• 22. Sheikh K, Coxson HO, Parraga G. This is what COPD looks like. Respirology 21(2), 224–236 (2016).
  MedlineGoogle Scholar
• 23. Kessler R, Partridge MR, Miravitlles M et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur. Respir. J. 37(2), 264–272 (2011).
  Medline CASGoogle Scholar
• 24. Murgia X, Loretz B, Hartwig O et al. The role of mucus on drug transport and its potential to affect therapeutic outcomes. Adv. Drug Deliv. Rev. 124, 82–97 (2018).
  Medline CASGoogle Scholar
• 25. Passi M, Shahid S, Chockalingam S et al. Conventional and nanotechnology based approaches to combat chronic obstructive pulmonary disease: implications for chronic airway diseases. Int. J. Nanomed. 3803–3826 (2020). •• Discusses some of the antioxidant therapies now utilized in the treatment and management of chronic airway diseases such as chronic obstructive pulmonary disease and asthma, with emphasis on recent developments in nanotechnology-based therapeutics.
  MedlineGoogle Scholar
• 26. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 5 (9), 691 (2017).
  MedlineGoogle Scholar
• 27. Beasley R. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 351(9111), 1225–1232 (1998).
  MedlineGoogle Scholar
• 28. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin. Chest Med. 32(4), 605–644 (2011).
  MedlineGoogle Scholar
• 29. Zhu A, Lee D, Shim H. Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin. Oncol. 38(1), 55–69 (2011).
  Medline CASGoogle Scholar
• 30. Miele L, Cordella-Miele E, Xing M et al. Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca²⁺-induced arachidonic acid release by epithelial cells. DNA Cell Biol. 16(6), 749–759 (1997).
  Medline CASGoogle Scholar
• 31. Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the ΔF508 conformational defect. Trends Mol. Med. 18(2), 81–91 (2012).
  Medline CASGoogle Scholar
• 32. Pai M, Behr MA, Dowdy D et al. Tuberculosis. Nat. Rev. Dis. Prim. 2(1), 16076 (2016).
  MedlineGoogle Scholar
• 33. Zarogoulidis P, Kioumis I, Pitsiou G et al. Pneumothorax: from definition to diagnosis and treatment. J. Thorac. Dis. 6(Suppl. 4), S372 (2014).
  MedlineGoogle Scholar
• 34. Tokuda H. Various aspects of acinar lesions – the key finding of pulmonary tuberculosis on HRCT. Kekkaku 84(8), 551–557 (2009).
  MedlineGoogle Scholar
• 35. Mitchell MJ, Billingsley MM, Haley RM et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20(2), 101–124 (2021).
  Medline CASGoogle Scholar
• 36. Van Rijt SH, Bein T, Meiners S. Medical nanoparticles for next generation drug delivery to the lungs. Eur. Respir. J. 44(3), 765–774 (2014).
  Medline CASGoogle Scholar
• 37. Suk JS, Boylan NJ, Trehan K et al. N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. Mol. Ther. 19(11), 1981–1989 (2011).
  Medline CASGoogle Scholar
• 38. Rytting E, Nguyen J, Wang X et al. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opinion on Drug Deliv. 5(6), 629–639 (2008).
  Medline CASGoogle Scholar
• 39. Schütz CA, Juillerat-Jeanneret L, Mueller H et al. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine 8(3), 449–467 (2013).
  CASGoogle Scholar
• 40. Shuvaev VV, Tliba S, Pick J et al. Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates. J. Control. Rel. 149(3), 236–241 (2011).
  Medline CASGoogle Scholar
• 41. Myerson JW, McPherson O, Defrates KG et al. Cross-linker-modulated nanogel flexibility correlates with tunable targeting to a sterically impeded endothelial marker. ACS Nano 13(10), 11409–11421 (2019).
  Medline CASGoogle Scholar
• 42. Coll Ferrer MC, Shuvaev VV, Zern BJ, Composto RJ, Muzykantov VR, Eckmann DM. ICAM-1 targeted nanogels loaded with dexamethasone alleviate pulmonary inflammation. PLOS ONE 9(7), e102329 (2014).
  MedlineGoogle Scholar
• 43. Myerson JW, Braender B, McPherson O et al. Flexible nanoparticles reach sterically obscured endothelial targets inaccessible to rigid nanoparticles. Adv. Mater. 30(32), 1802373 (2018).
  Google Scholar
• 44. Shuvaev VV, Khoshnejad M, Pulsipher KW et al. Spatially controlled assembly of affinity ligand and enzyme cargo enables targeting ferritin nanocarriers to caveolae. Biomaterials 185, 348–359 (2018).
  Medline CASGoogle Scholar
• 45. Geng Y, Dalhaimer P, Cai S et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2(4), 249–255 (2007).
  Medline CASGoogle Scholar
• 46. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA 103(13), 4930–4934 (2006).
  Medline CASGoogle Scholar
• 47. Alexis F, Pridgen E, Molnar LK et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharmaceut. 5(4), 505–515 (2008).
  Medline CASGoogle Scholar
• 48. Muro S, Garnacho C, Champion JA et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol. Ther. 16(8), 1450–1458 (2008).
  Medline CASGoogle Scholar
• 49. Nel AE, Mädler L, Velegol D et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8(7), 543–557 (2009).
  Medline CASGoogle Scholar
• 50. Yoo JW, Doshi N, Mitragotri S. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv. Drug Deliv. Reviews 63(14-15), 1247–1256 (2011).
  Medline CASGoogle Scholar
• 51. Amoozgar Z, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 4(2), 219–233 (2012).
  Medline CASGoogle Scholar
• 52. Monopoli MP, Åberg C, Salvati A et al. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7(12), 779–786 (2012).
  Medline CASGoogle Scholar
• 53. Ruge CA, Schaefer UF, Herrmann J et al. The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles. PLOS ONE 7(7), e40775 (2012).
  Medline CASGoogle Scholar
• 54. Bahadori M, Mohammadi F. Nanomedicine for respiratory diseases. Tanaffos 11(4), 18 (2012).
  MedlineGoogle Scholar
• 55. Shuvaev VV, Christofidou-Solomidou M, Scherpereel A et al. Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium. J. Control. Rel. 118(2), 235–244 (2007).
  Medline CASGoogle Scholar
• 56. Liong M, Lu J, Kovochich M et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2(5), 889–896 (2008).
  Medline CASGoogle Scholar
• 57. Al-Jamal WT, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc. Chem. Res. 44(10), 1094–1104 (2011).
  Medline CASGoogle Scholar
• 58. Ruge CA, Kirch J, Lehr CM. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers – therapeutic possibilities and technological challenges. Lancet Respir. Med. 1(5), 402–413 (2013).
  Medline CASGoogle Scholar
• 59. Gupta AK, Singh A, Singh S. Diagnosis of tuberculosis: nanodiagnostics approaches. NanoBioMedicine 261–282 (2020). •• Explains the current tuberculosis diagnostic techniques and emphasizes the most recent developments in Mycobacterium tuberculosis detection testing based on nanotechnology.
  Google Scholar
• 60. Brenner JS, Bhamidipati K, Glassman PM et al. Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions. Nanomedicine: Nanotechnol. Bio. Med. 13(4), 1495–1506 (2017).
  CASGoogle Scholar
• 61. Shuvaev VV, Brenner JS, Muzykantov VR. Targeted endothelial nanomedicine for common acute pathological conditions. J. Control. Rel. 219, 576–595 (2015).
  Medline CASGoogle Scholar
• 62. Brenner JS, Greineder C, Shuvaev V etal. Endothelial nanomedicine for the treatment of pulmonary disease. Expert Opin. Drug Deliv. 12(2), 239–261 (2015).
  Medline CASGoogle Scholar
• 63. Muzykantov VR. Biomedical aspects of targeted delivery of drugs to pulmonary endothelium. Expert Opin. Drug Deliv. 2(5), 909–926 (2005).
  Medline CASGoogle Scholar
• 64. Qiao Q, Liu X, Yang T et al. Nanomedicine for acute respiratory distress syndrome: the latest application, targeting strategy, and rational design. Acta Pharmaceut. Sinica B. 11(10), 3060–3091 (2021).
  Medline CASGoogle Scholar
• 65. Oyaizu T, Fung SY, Shiozaki A et al. Src tyrosine kinase inhibition prevents pulmonary ischemia-reperfusion-induced acute lung injury. Intensive Care Med. 38, 894–905 (2012).
  Medline CASGoogle Scholar
• 66. Myerson JW, Patel PN, Rubey KM et al. Supramolecular arrangement of protein in nanoparticle structures predicts nanoparticle tropism for neutrophils in acute lung inflammation. Nat. Nanotechnol. 17(1), 86–97 (2022).
  Medline CASGoogle Scholar
• 67. Murciano JC, Harshaw DW, Ghitescu L et al. Vascular immunotargeting to endothelial surface in a specific macrodomain in alveolar capillaries. Am. J. Respir. Crit. Care Med. 164(7), 1295–1302 (2001).
  Medline CASGoogle Scholar
• 68. Preissler G, Loehe F, Huff IV et al. Targeted endothelial delivery of nanosized catalase immunoconjugates protects lung grafts donated after cardiac death. Transplantation 92(4), 380 (2011).
  Medline CASGoogle Scholar
• 69. Christofidou-Solomidou M, Scherpereel A, Wiewrodt R et al. PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. American J. Physiology-Lung Cell. Mol. Physiol. 285(2), L283–L292 (2003).
  Medline CASGoogle Scholar
• 70. Muro S, Cui X, Gajewski C, Murciano JC, Muzykantov VR, Koval M. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am. J. Physiol. Cell Physiol. 285(5), C1339–C1347 (2003).
  Medline CASGoogle Scholar
• 71. Shuvaev VV, Christofidou-Solomidou M, Bhora F et al. Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J. Pharmacol. Exp. Ther. 331(2), 404–411 (2009).
  Medline CASGoogle Scholar
• 72. Han J, Shuvaev VV, Muzykantov VR. Catalase and superoxide dismutase conjugated with platelet-endothelial cell adhesion molecule antibody distinctly alleviate abnormal endothelial permeability caused by exogenous reactive oxygen species and vascular endothelial growth factor. J. Pharmacol. Exp. Ther. 338(1), 82–91 (2011).
  Medline CASGoogle Scholar
• 73. Sweitzer TD, Thomas AP, Wiewrodt R et al. PECAM-directed immunotargeting of catalase: specific, rapid and transient protection against hydrogen peroxide. Free Radic. Biol. Med. 34(8), 1035–1046 (2003).
  Medline CASGoogle Scholar
• 74. Chacko AM, Han J, Greineder CF et al. Collaborative enhancement of endothelial targeting of nanocarriers by modulating platelet-endothelial cell adhesion molecule-1/cD31 epitope engagement. ACS Nano 9(7), 6785–6793 (2015).
  Medline CASGoogle Scholar
• 75. Shuvaev VV, Ilies MA, Simone E et al. Endothelial targeting of antibody-decorated polymeric filomicelles. ACS Nano 5(9), 6991–6999 (2011).
  Medline CASGoogle Scholar
• 76. Ding BS, Gottstein C, Grunow A et al. Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood 106(13), 4191–4198 (2005).
  Medline CASGoogle Scholar
• 77. Garnacho C, Shuvaev V, Thomas A et al. RhoA activation and actin reorganization involved in endothelial CAM-mediated endocytosis of anti-PECAM carriers: critical role for tyrosine 686 in the cytoplasmic tail of PECAM-1. Blood 111(6), 3024–3033 (2008).
  Medline CASGoogle Scholar
• 78. Parhiz H, Shuvaev VV, Pardi N et al. PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake. J. Control. Rel. 291, 106–115 (2018).
  Medline CASGoogle Scholar
• 79. Kiseleva R, Greineder CF, Villa CH et al. Mechanism of collaborative enhancement of binding of paired antibodies to distinct epitopes of platelet endothelial cell adhesion molecule-1. PLOS ONE 12(1), e0169537 (2017).
  MedlineGoogle Scholar
• 80. Shuvaev VV, Muro S, Arguiri E et al. Size and targeting to PECAM vs ICAM control endothelial delivery, internalization and protective effect of multimolecular SOD conjugates. J. Control. Rel. 234, 115–123 (2016).
  Medline CASGoogle Scholar
• 81. Shuvaev VV, Tliba S, Nakada M et al. Platelet-endothelial cell adhesion molecule-1-directed endothelial targeting of superoxide dismutase alleviates oxidative stress caused by either extracellular or intracellular superoxide. J. Pharmacol. Exp. Ther. 323(2), 450–457 (2007).
  Medline CASGoogle Scholar
• 82. Atochina EN, Balyasnikova IV, Danilov SM et al. Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress. Am. J. Physiol. Lung Cell. Mol. Physiol. 275(4), L806–L817 (1998).
  Medline CASGoogle Scholar
• 83. Kartha S, Yan L, Weisshaar CL et al. Superoxide dismutase-loaded porous polymersomes as highly efficient antioxidants for treating neuropathic pain. Adv. Healthc. Mater. 6(17), 1700500 (2017).
  Google Scholar
• 84. Simone EA, Dziubla TD, Discher DE et al. Filamentous polymer nanocarriers of tunable stiffness that encapsulate the therapeutic enzyme catalase. Biomacromolecules 10(6), 1324–1330 (2009).
  Medline CASGoogle Scholar
• 85. Simone EA, Dziubla TD, Arguiri E et al. Loading PEG-catalase into filamentous and spherical polymer nanocarriers. Pharm. Res. 26, 250–260 (2009).
  Medline CASGoogle Scholar
• 86. Dziubla TD, Shuvaev VV, Hong NK et al. Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials 29(2), 215–227 (2008).
  Medline CASGoogle Scholar
• 87. Simone EA, Dziubla TD, Colon-Gonzalez F et al. Effect of polymer amphiphilicity on loading of a therapeutic enzyme into protective filamentous and spherical polymer nanocarriers. Biomacromolecules 8(12), 3914–3921 (2007).
  Medline CASGoogle Scholar
• 88. Khoshnejad M, Shuvaev VV, Pulsipher KW et al. Vascular accessibility of endothelial targeted ferritin nanoparticles. Bioconjug. Chem. 27(3), 628–637 (2016).
  Medline CASGoogle Scholar
• 89. Chorny M, Hood E, Levy RJ, Muzykantov VR. Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. J. Control. Rel. 146(1), 144–151 (2010).
  Medline CASGoogle Scholar
• 90. Danilov SM, Gavrilyuk VD, Franke FE et al. Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am. J. Physiol. Lung Cell. Mol. Physiol. 280(6), L1335–L1347 (2001).
  Medline CASGoogle Scholar
• 91. Muro S, Muzykantov V. Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. Curr. Pharm. Des. 11(18), 2383–2401 (2005).
  Medline CASGoogle Scholar
• 92. Shuvaev VV, Han J, Yu KJ et al. PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J. 25(1), 348 (2011).
  MedlineGoogle Scholar
• 93. Shuvaev VV, Han J, Tliba S et al. Anti-inflammatory effect of targeted delivery of SOD to endothelium: mechanism, synergism with NO donors and protective effects in vitro and in vivo. PLOS ONE 8(10), e77002 (2013).
  Medline CASGoogle Scholar
• 94. Howard MD, Greineder CF, Hood ED, Muzykantov VR. Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation. J. Control. Rel. 177, 34–41 (2014).
  Medline CASGoogle Scholar
• 95. Garnacho C, Albelda SM, Muzykantov VR, Muro S. Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J. Control. Rel. 130(3), 226–233 (2008).
  Medline CASGoogle Scholar
• 96. Ding BS, Hong N, Christofidou-Solomidou M et al. Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am. J. Respir. Crit. Care Med. 180(3), 247–256 (2009).
  Medline CASGoogle Scholar
• 97. Ding BS, Hong N, Murciano JC et al. Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood 111(4), 1999–2006 (2008).
  Medline CASGoogle Scholar
• 98. Greineder CF, Johnston IH, Villa CH et al. ICAM-1-targeted thrombomodulin mitigates tissue factor-driven inflammatory thrombosis in a human endothelialized microfluidic model. Blood Adv. 1(18), 1452–1465 (2017).
  Medline CASGoogle Scholar
• 99. Greineder CF, Chacko AM, Zaytsev S et al. Vascular immunotargeting to endothelial determinant ICAM-1 enables optimal partnering of recombinant scFv-thrombomodulin fusion with endogenous cofactor. PLOS ONE 8(11), e80110 (2013).
  MedlineGoogle Scholar
• 100. Carnemolla R, Greineder CF, Chacko AM et al. Platelet endothelial cell adhesion molecule targeted oxidant-resistant mutant thrombomodulin fusion protein with enhanced potency in vitro and in vivo. J. Pharmacol. Exp. Ther. 347(2), 339–345 (2013).
  Medline CASGoogle Scholar
• 101. Hood ED, Chorny M, Greineder CF et al. Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation. Biomaterials 35(11), 3708–3715 (2014).
  Medline CASGoogle Scholar
• 102. Howard MD, Hood ED, Greineder CF, Alferiev IS, Chorny M, Muzykantov V. Targeting to endothelial cells augments the protective effect of novel dual bioactive antioxidant/anti-inflammatory nanoparticles. Mol. Pharm. 11(7), 2262–2270 (2014).
  Medline CASGoogle Scholar
• 103. Hood ED, Greineder CF, Dodia C et al. Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo. J. Control. Rel. 163(2), 161–169 (2012).
  Medline CASGoogle Scholar
• 104. Anselmo AC, Mitragotri S. Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles. J. Control. Rel. 190, 531–541 (2014).
  Medline CASGoogle Scholar
• 105. Zelepukin IV, Yaremenko AV, Shipunova VO et al. Nanoparticle-based drug delivery: via RBC-hitchhiking for the inhibition of lung metastases growth. Nanoscale 11(4), 1636–1646 (2019).
  Medline CASGoogle Scholar
• 106. Brenner JS, Pan DC, Myerson JW et al. Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude. Nat. Commun. 9(1), 2684 (2018).
  MedlineGoogle Scholar
• 107. Xu Y, Xiang J, Zhao H et al. Human amniotic fluid stem cells labeled with up-conversion nanoparticles for imaging-monitored repairing of acute lung injury. Biomaterials 100, 91–100 (2016).
  Medline CASGoogle Scholar
• 108. Guagliardo R, Pérez-Gil J, De Smedt S et al. Pulmonary surfactant and drug delivery: focusing on the role of surfactant proteins. J. Control. Rel. 291, 116–126 (2018).
  Medline CASGoogle Scholar
• 109. Hsu CY, Sung CT, Aljuffali IA et al. Intravenous anti-MRSA phosphatiosomes mediate enhanced affinity to pulmonary surfactants for effective treatment of infectious pneumonia. Nanomed. Nanotechnol. Biol. Med. 14(2), 215–225 (2018).
  CASGoogle Scholar
• 110. Tavano L, Pinazo A, Abo-Riya M et al. Cationic vesicles based on biocompatible diacyl glycerol-arginine surfactants: physicochemical properties, antimicrobial activity, encapsulation efficiency and drug release. Colloids Surf. B Biointerfaces 120, 160–167 (2014).
  Medline CASGoogle Scholar
• 111. Chen XY, Wang SM, Li N et al. Creation of lung-targeted dexamethasone immunoliposome and its therapeutic effect on bleomycin-induced lung injury in rats. PLOS ONE 8(3), e58275 (2013).
  Medline CASGoogle Scholar
• 112. Li N, Weng D, Wang SM et al. Surfactant protein-a nanobody-conjugated liposomes loaded with methylprednisolone increase lung-targeting specificity and therapeutic effect for acute lung injury. Drug Deliv. 24(1), 1770–1781 (2017).
  Medline CASGoogle Scholar
• 113. Hickey AJ. Controlled delivery of inhaled therapeutic agents. J. Control. Rel. 190, 182–188 (2014).
  Medline CASGoogle Scholar
• 114. Scherließ R. Future of nanomedicines for treating respiratory diseases. Expert Opin. Drug Deliv. 16(1), 59–68 (2019).
  Medline CASGoogle Scholar
• 115. Mejías JC, Forrest OA, Margaroli C et al. Neutrophil-targeted, protease-activated pulmonary drug delivery blocks airway and systemic inflammation. JCI Insight 4(23), (2019).
  MedlineGoogle Scholar
• 116. Machhi J, Shahjin F, Das S et al. Nanocarrier vaccines for SARS-CoV-2. Adv. Drug Deliv. Reviews 171, 215–239 (2021).
  Medline CASGoogle Scholar
• 117. Ma X, Zou F, Yu F et al. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 53(6), 1315–1330 (2020).
  Medline CASGoogle Scholar
• 118. Pati R, Shevtsov M, Sonawane A. Nanoparticle vaccines against infectious diseases. Front. Immunol. 9, 2224 (2018).
  MedlineGoogle Scholar
• 119. Valavanidis A, Vlachogianni T, Fiotakis K, Loridas S. Pulmonary oxidative stress, inflammation and cancer: respirable particulate matter, fibrous dusts and ozone as major causes of lung carcinogenesis through reactive oxygen species mechanisms. Int. J. Environ. Res. Public Health 10(9), 3886–3907 (2013).
  MedlineGoogle Scholar
• 120. Pedre B, Barayeu U, Ezeriņa D et al. The mechanism of action of N-acetylcysteine (NAC): the emerging role of H₂S and sulfane sulfur species. Pharmacol. Therapeut. 228, 107916 (2021).
  Medline CASGoogle Scholar
• 121. Rahman I. Antioxidant therapies in COPD. Int. J. Chronic Obstructive Pulmon. Dis. 1(1), 15–29 (2006).
  Medline CASGoogle Scholar
• 122. Aggarwal V, Tuli HS, Varol A et al. Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements. Biomolecules 9(11), 735 (2019).
  Medline CASGoogle Scholar
• 123. Braga PC, Dal Sasso M, Sala MT et al. Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneimittel-Forschung 49(4), 344–350 (1999).
  Medline CASGoogle Scholar
• 124. Rahman I. Antioxidant therapeutic advances in COPD. Therapeut. Adv. Respirat. Dis. 2(6), 351–374 (2008).
  MedlineGoogle Scholar
• 125. Forni C, Facchiano F, Bartoli M et al. Beneficial role of phytochemicals on oxidative stress and age-related diseases. BioMed Res. Int. 2019 (2019).
  Google Scholar
• 126. Meyer M, Wagner E. pH-responsive shielding of non-viral gene vectors. Expert Opin. Drug Deliv. 3(5), 563–571 (2006).
  Medline CASGoogle Scholar
• 127. Hatakeyama H, Akita H, Kogure K et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Therapy 14(1), 68–77 (2007).
  Medline CASGoogle Scholar
• 128. Vij N. Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential. Expert Opin. Drug Deliv. 8(9), 1105–1109 (2011).
  Medline CASGoogle Scholar
• 129. Geiser M, Quaile O, Wenk A et al. Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease. Part. Fibre Toxicol. 10(1), 1–10 (2013).
  MedlineGoogle Scholar
• 130. Roulet A, Armand L, Dagouassat M et al. Intratracheally administered titanium dioxide or carbon black nanoparticles do not aggravate elastase-induced pulmonary emphysema in rats. BMC Pulm. Med. 12, 1–12 (2012).
  MedlineGoogle Scholar
• 131. Al Faraj A, Shaik AS, Afzal S, Al Sayed B, Halwani R. MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles. Int. J. Nanomed. 9, 1491 (2014).
  MedlineGoogle Scholar
• 132. Acosta MF, Abrahamson MD, Encinas-Basurto D, Fineman JR, Black SM, Mansour HM. Inhalable nanoparticles/microparticles of an AMPK and Nrf2 activator for targeted pulmonary drug delivery as dry powder inhalers. The AAPS J. 23, 1–14 (2021).
  Google Scholar
• 133. Konstan MW, Davis PB, Wagener JS et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Human Gene Therapy 15(12), 1255–1269 (2004).
  Medline CASGoogle Scholar
• 134. Cartiera MS, Ferreira EC, Caputo C, Egan ME, Caplan MJ, Saltzman WM. Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin. Mol. Pharm. 7(1), 86–93 (2010).
  Medline CASGoogle Scholar
• 135. Guan S, Munder A, Hedtfeld S et al. Self-assembled peptide–poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis. Nat. Nanotechnol. 14(3), 287–297 (2019).
  Medline CASGoogle Scholar
• 136. Tan M, Reyes-Ortega F, Schneider-Futschik EK. Magnetic nanoparticle-based drug delivery approaches for preventing and treating biofilms in cystic fibrosis. Magnetochemistry 6(4), 72 (2020).
  CASGoogle Scholar
• 137. Bae KH, Lee JY, Lee SH, Park TG, Nam YS. Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging. Adv. Healthc. Mater. 2(4), 576–584 (2013).
  Medline CASGoogle Scholar
• 138. Kim H, Park HT, Tae YM et al. Bioimaging and pulmonary applications of self-assembled Flt1 peptide-hyaluronic acid conjugate nanoparticles. Biomaterials 34(33), 8478–8490 (2013).
  Medline CASGoogle Scholar
• 139. Chen X, Huang W, Kwan Wong BC et al. Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int. J. Nanomed. 1139–1148 (2012).
  MedlineGoogle Scholar
• 140. Lanza GM, Jenkins J, Schmieder AH et al. Anti-angiogenic nanotherapy inhibits airway remodeling and hyper-responsiveness of dust mite triggered asthma in the brown Norway rat. Theranostics 7(2), 377 (2017).
  Medline CASGoogle Scholar
• 141. Mueller C, Flotte TR. Gene therapy for cystic fibrosis. Clin. Rev. Allergy Immunol. 35(3), 164–178 (2008).
  Medline CASGoogle Scholar
• 142. Costa-Gouveia J, Pancani E, Jouny S et al. Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. Sci. Rep. 7(1), 5390 (2017).
  MedlineGoogle Scholar
• 143. Arafa MG, Ayoub BM. Nano-vesicles of salbutamol sulphate in metered dose inhalers: formulation, characterization and in vitro evaluation. Int. J. Appl. Pharm. 9(6), 100–105 (2017).
  CASGoogle Scholar
• 144. Wu YL, Park K, Soo RA et al. INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small-cell lung cancer. BMC Cancer 11(1) 1–7 (2011).
  MedlineGoogle Scholar
• 145. Alton EWFW, Armstrong DK, Ashby D et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir. Med. 3(9), 684–691 (2015).
  Medline CASGoogle Scholar
• 146. Meers P, Neville M, Malinin V et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 61(4), 859–868 (2008).
  Medline CASGoogle Scholar
• 147. Moreno-Sastre M, Pastor M, Salomon CJ et al. Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy. J. Antimicrob. Chemother. 70(11), 2945–2955 (2015).
  Medline CASGoogle Scholar
• 148. Mohamed A, Kunda NK, Ross K, Hutcheon GA, Saleem IY. Polymeric nanoparticles for the delivery of miRNA to treat chronic obstructive pulmonary disease (COPD). Eur. J. Pharm. Biopharm. 136, 1–8 (2019).
  Medline CASGoogle Scholar
• 149. Ho DK, Murgia X, De Rossi C et al. Squalenyl hydrogen sulfate nanoparticles for simultaneous delivery of tobramycin and an alkylquinolone quorum sensing inhibitor enable the eradication of P. aeruginosa biofilm infections. Angew. Chemie Int. Ed. 132(26), 10378–10382 (2020).
  Google Scholar
• 150. Wang Y, Yuan Q, Feng W et al. Targeted delivery of antibiotics to the infected pulmonary tissues using ROS-responsive nanoparticles. J. Nanobiotechnol. 17(1), 1–16 (2019).
  MedlineGoogle Scholar
• 151. Hwang AA, Lee BY, Clemens DL, Dillon BJ, Zink JI, Horwitz MA. Tuberculosis: pH-responsive isoniazid-loaded nanoparticles markedly improve tuberculosis treatment in mice. Small 11(38), 5066–5078 (2015).
  Medline CASGoogle Scholar
• 152. Keil TWM, Feldmann DP, Costabile G, Zhong Q, da Rocha S, Merkel OM. Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles. Eur. J. Pharm. Biopharm. 143, 61–69 (2019).
  Medline CASGoogle Scholar
• 153. Konstan MW, Davis PB, Wagener JS et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum. Gene Ther. 15(12), (2004).
  MedlineGoogle Scholar
• 154. Sanchez-Guzman D, Le Guen P, Villeret B et al. Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity. Biomaterials 217, 119308 (2019).
  Medline CASGoogle Scholar
• 155. Ellis T, Chiappi M, García-Trenco A et al. Multimetallic microparticles increase the potency of rifampicin against intracellular Mycobacterium tuberculosis. ACS Nano. 12(6), 5228–5240 (2018).
  Medline CASGoogle Scholar
• 156. Ahmad FJ, Mittal G, Jain GK et al. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. Eur. J. Pharm. Biopharm. 71(2), 282–291 (2009).
  MedlineGoogle Scholar
• 157. Liu B, Cao W, Qiao G et al. Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer. Acta Biomater. 99, 307–319 (2019).
  Medline CASGoogle Scholar
• 158. Reid G, Kao SC, Pavlakis N et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics 8(8), (2016).
  Google Scholar
• 159. Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb. Perspect. Med. 5(9), a017863 (2015).
  MedlineGoogle Scholar
• 160. Robinson E, MacDonald KD, Slaughter K et al. Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis. Mol. Ther. 26(8), 2034–2046 (2018).
  Medline CASGoogle Scholar
• 161. Da Silva AL, Martini SV, Abreu SC et al. DNA nanoparticle-mediated thymulin gene therapy prevents airway remodeling in experimental allergic asthma. J. Control. Rel. 180, 125–133 (2014).
  MedlineGoogle Scholar
• 162. Zhao Y, Xu A, Xu Q et al. Bone marrow mesenchymal stem cell transplantation for treatment of emphysemic rats. Int. J. Clin. Exp. Med. 7(4), 968 (2014).
  MedlineGoogle Scholar
• 163. Rojas M, Xu J, Woods CR et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am. J. Respir. Cell Mol. Biol. 33(2), 145–152 (2005).
  Medline CASGoogle Scholar
• 164. Howard M, Zern BJ, Anselmo AC etal. Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano 8(5) 4100–4132 (2014).
  Medline CASGoogle Scholar
• 165. Parhiz H, Khoshnejad M, Myerson JW et al. Unintended effects of drug carriers: big issues of small particles. Adv. Drug Deliv. Reviews 130, 90–112 (2018).
  Medline CASGoogle Scholar
• 166. Bourdon JA, Saber AT, Jacobsen NR et al. Carbon black nanoparticle instillation induces sustained inflammation and genotoxicity in mouse lung and liver. Part. Fibre Toxicol. 9, 1–14 (2012).
  MedlineGoogle Scholar
• 167. Glassman PM, Myerson JW, Ferguson LT et al. Targeting drug delivery in the vascular system: focus on endothelium. Adv. Drug Deliv. Reviews 157, 96–117 (2020).
  Medline CASGoogle Scholar